LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...

Please provide your email address to receive an email when new articles are posted on . In long QT syndrome, patients doing vigorous exercise did not have more events than those doing nonvigorous ...

For many years, moderate alcohol intake and its effect on health have been subject to much debate, particularly concerning cardiovascular health. Indeed, light-to-moderate use of alcohol has been ...

A machine learning model was more effective at detecting congenital long QT syndrome on resting ECGs than manual measurement of QT intervals by arrhythmia experts, in a new study. Researchers ...

Please provide your email address to receive an email when new articles are posted on . In people with long QT syndrome, vigorous exercise did not raise risk for death or arrhythmias vs. nonvigorous ...

Less than 1 percent of the population has been diagnosed with Long QT syndrome – a rare heart condition that can cause chaotic, sometimes fatal, heart rhythms. Now, Virginia Tech researchers at the ...

An innovative analysis of shared segments within the genome - an indication of distant "relatedness" - has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal ...

Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...

In many low- and middle-income countries, pediatric cardiologists can't help children with congenital heart conditions because of a critical hurdle. They don't have easy access to advanced diagnostic ...

ROCHESTER, MN — A significant number of patients given implantable cardioverter defibrillators (ICDs) for long-QT syndrome (LQTS) receive them for reasons outside of current guidelines, and many ...